Solid Bioscience Financials
Financial Health Signals
Solid Bioscience passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Solid Bioscience generates $0.80 in operating cash flow (-$100.0M OCF vs -$124.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Solid Bioscience earns $-381.6 in operating income for every $1 of interest expense (-$129.7M vs $340K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Solid Bioscience (SLDB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Solid Bioscience's EBITDA was -$127.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 25.2% from the prior year.
Solid Bioscience generated -$100.7M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 5.2% from the prior year.
Solid Bioscience reported -$124.7M in net income in fiscal year 2024. This represents a decrease of 29.9% from the prior year.
Solid Bioscience earned $-3.06 per diluted share (EPS) in fiscal year 2024. This represents an increase of 36.6% from the prior year.
Solid Bioscience held $80.2M in cash against $0 in long-term debt as of fiscal year 2024.
Solid Bioscience had 40M shares outstanding in fiscal year 2024. This represents an increase of 98.5% from the prior year.
Solid Bioscience invested $96.4M in research and development in fiscal year 2024. This represents an increase of 25.9% from the prior year.
Solid Bioscience invested $654K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 56.8% from the prior year.
SLDB Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $38.9M+42.2% | $27.3M | N/A | $16.7M | N/A | $14.0M-39.6% | $23.2M+16.2% | $19.9M |
| SG&A Expenses | $9.2M+17.1% | $7.9M | N/A | $6.4M | N/A | $7.1M+4.0% | $6.9M-6.8% | $7.4M |
| Operating Income | -$48.1M-36.6% | -$35.2M | N/A | -$23.1M | N/A | -$21.1M+16.7% | -$25.4M0.0% | -$25.4M |
| Interest Expense | -$336K-509.8% | $82K | N/A | $106K | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0 | N/A | $0 | N/A | $0 | $0 | $0 |
| Net Income | -$45.8M-39.9% | -$32.7M | N/A | -$21.0M | N/A | -$20.4M+18.7% | -$25.1M+0.9% | -$25.3M |
| EPS (Diluted) | $-0.48+39.2% | $-0.79 | N/A | $-1.05 | N/A | $-2.71 | $-3.33+1.2% | $-3.37 |
SLDB Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $273.9M+45.2% | $188.7M+14.4% | $164.9M-10.7% | $184.7M-29.0% | $260.3M+41.1% | $184.5M-11.5% | $208.5M+0.5% | $207.6M |
| Current Assets | $244.9M+55.7% | $157.3M+21.2% | $129.7M-12.5% | $148.3M-32.5% | $219.6M+48.9% | $147.5M-13.5% | $170.4M-14.2% | $198.6M |
| Cash & Equivalents | $61.4M-23.5% | $80.2M+8.4% | $74.0M+50.9% | $49.0M-68.4% | $155.4M+218.5% | $48.8M-10.2% | $54.3M-58.1% | $129.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $56.0M+8.8% | $51.4M+33.7% | $38.5M-4.7% | $40.4M-16.9% | $48.6M+17.9% | $41.2M-10.9% | $46.3M+109.8% | $22.0M |
| Current Liabilities | $36.3M+20.1% | $30.3M+108.4% | $14.5M-8.2% | $15.8M-29.7% | $22.5M+33.0% | $16.9M-22.1% | $21.7M-0.1% | $21.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $217.9M+58.8% | $137.2M+8.5% | $126.5M-12.4% | $144.4M-31.8% | $211.7M+47.7% | $143.3M-11.7% | $162.2M-12.5% | $185.5M |
| Retained Earnings | -$908.0M-15.9% | -$783.5M-18.9% | -$658.8M-3.2% | -$638.4M-13.4% | -$562.7M-2.8% | -$547.6M-3.9% | -$527.2M-5.0% | -$502.1M |
SLDB Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$33.5M-12.9% | -$29.6M-42.4% | -$20.8M-16.3% | -$17.9M+48.1% | -$34.5M-68.8% | -$20.4M-28.7% | -$15.9M+41.6% | -$27.2M |
| Capital Expenditures | $85K-58.3% | $204K+126.7% | $90K-76.5% | $383K-55.3% | $856K+2.0% | $839K-26.1% | $1.1M+517.4% | $184K |
| Free Cash Flow | -$33.6M-12.4% | -$29.8M-42.7% | -$20.9M-14.4% | -$18.3M+48.3% | -$35.3M-66.1% | -$21.3M-25.0% | -$17.0M+37.8% | -$27.4M |
| Investing Cash Flow | -$45.3M-217.4% | $38.6M-14.9% | $45.3M+283.9% | -$24.6M-137.3% | $66.1M+343.4% | $14.9M+125.0% | -$59.6M-257.9% | $37.7M |
| Financing Cash Flow | $1.2M-83.1% | $6.9M+1274.3% | $505K | $0-100.0% | $74.7M+7473800.0% | -$1K-101.4% | $73K+231.8% | $22K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SLDB Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -16.7%-1.3pp | -15.4% | N/A | -11.4% | N/A | -11.1%+1.0pp | -12.0%+0.2pp | -12.2% |
| Current Ratio | 6.74+1.5 | 5.20-3.7 | 8.94-0.4 | 9.38-0.4 | 9.76+1.0 | 8.72+0.9 | 7.85-1.3 | 9.13 |
| Debt-to-Equity | 0.26-0.1 | 0.37+0.1 | 0.30+0.0 | 0.28+0.1 | 0.23-0.1 | 0.290.0 | 0.29+0.2 | 0.12 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Solid Bioscience profitable?
No, Solid Bioscience (SLDB) reported a net income of -$124.7M in fiscal year 2024.
What is Solid Bioscience's earnings per share (EPS)?
Solid Bioscience (SLDB) reported diluted earnings per share of $-3.06 for fiscal year 2024. This represents a 36.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Solid Bioscience's EBITDA?
Solid Bioscience (SLDB) had EBITDA of -$127.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Solid Bioscience's free cash flow?
Solid Bioscience (SLDB) generated -$100.7M in free cash flow during fiscal year 2024. This represents a -5.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Solid Bioscience's operating cash flow?
Solid Bioscience (SLDB) generated -$100.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Solid Bioscience's total assets?
Solid Bioscience (SLDB) had $188.7M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Solid Bioscience's capital expenditures?
Solid Bioscience (SLDB) invested $654K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Solid Bioscience spend on research and development?
Solid Bioscience (SLDB) invested $96.4M in research and development during fiscal year 2024.
How many shares does Solid Bioscience have outstanding?
Solid Bioscience (SLDB) had 40M shares outstanding as of fiscal year 2024.
What is Solid Bioscience's current ratio?
Solid Bioscience (SLDB) had a current ratio of 5.20 as of fiscal year 2024, which is generally considered healthy.
What is Solid Bioscience's debt-to-equity ratio?
Solid Bioscience (SLDB) had a debt-to-equity ratio of 0.37 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Solid Bioscience's return on assets (ROA)?
Solid Bioscience (SLDB) had a return on assets of -66.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Solid Bioscience's cash runway?
Based on fiscal year 2024 data, Solid Bioscience (SLDB) had $80.2M in cash against an annual operating cash burn of $100.0M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Solid Bioscience's Piotroski F-Score?
Solid Bioscience (SLDB) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Solid Bioscience's earnings high quality?
Solid Bioscience (SLDB) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Solid Bioscience cover its interest payments?
Solid Bioscience (SLDB) has an interest coverage ratio of -381.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.